|
|
 |
|
Viewing report
|
|
|
|
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Takeda Pacific, June 2007, Pages: 130
This report focuses on the market for biomarkers and tests used in pharma/ biotech drug R&D. The study reviews the market by looking at key alliances, pharma/ biotech research and development spending, trends, major diseases, applications and technologies. The research analyzed the future direction of biomarkers and related ‘-omic’ or pharmacogenomic (PGx) tests used in drug R&D. This report estimates the worldwide market value and growth (CAGR) of biomarkers and tests for pharma/ biotech R&D for the next five years.
Research-based pharma/ biotech companies face numerous challenges that are being overcome with newer business strategies or approaches that are discussed in this report. This business area is set for strong continued growth as biomarkers and tests in drug R&D enable new opportunities.
The report discusses ongoing government initiatives that foster worldwide development in targeted therapeutics, biomarkers and personalized medicine opportunities. Their expectation is to streamline commercializing new, safer, drugs and co-developed tests by integrating biomarkers and PGx tests into the critical path of drug R&D.
Traditional clinical trial designs will undergo key changes that integrate biomarkers and tests to provide more useful information in order for drug makers to make better product decisions. Some drug company executives expect biomarkers to enable a ‘sea change’ in how new drugs are developed as the blockbuster business model fades and transitions to new focused therapeutic approaches that gain traction in a few years.
Targeted therapies such as Herceptin, Gleevec, Erbitux, or Irressa are among new drug products that work in just a sub-set of patients that pass special pharmcogenomic tests designed for each product. Many drug companies are routinely using biomarkers in R&D and are increasingly adding drug-test projects to their product pipelines. The era of personalized medicine has arrived.
This study uses more than 42 figures and tables to illustrate its useful findings. The report offers detailed information including data tables about strategic alliances, technologies and so on. Thirty-one leading companies are profiled with details such as contact information, business overview, financial details and product information.
This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.
Customers who bought this item also bought
Biomarkers: The Future of Next-Generation Drug R&D
Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D -- Companies Products and WW Market, 2004-2009
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Biomarkers - Technologies, Markets and Companies
Companion Biomarkers in Drug Development
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Biomarkers 2008
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
Advances in Biomarkers
Biomarkers - Advanced Technologies and Global Market (2009-2014)
RNA Interference for Drug R&D: Applications, Alliances, Companies and WW Market to 2011
|
|
|
|
